Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST surveillance program (1998-2002)

Clinical Infectious Diseases

Volumn 36, Issue 8, 2003, Pages 963-970

  Karlowsky, James A ^a   Thornsberry, Clyde ^b   Jones, Mark E ^c   Evangelista, Alan T ^d   Critchley, Ian A ^a   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (United States)

^c Focus Technologies   (Netherlands)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE;

ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CORRELATION ANALYSIS; HUMAN; LINEAR REGRESSION ANALYSIS; LOWER RESPIRATORY TRACT; LUNG ASPIRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PREVALENCE; PRIORITY JOURNAL; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIAE; TRACHEA; TRACHEOBRONCHIAL TOILET; UNITED STATES; ADOLESCENT; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLINS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0037447017     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374052     Document Type: Article

References (29)

1. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45:1721-9.
2. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32(Suppl 2):S81-93.
3. Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance Study. Antimicrob Agents Chemother 1999; 43:1901-8.
4. Thornsberry C, lones ME, Hickey ML, et al. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999; 44:749-59.
5. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45:1037-42.
6. Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin Infect Dis 2002; 34(Suppl 1):S4-16.
7. Deshpande LM, Jones RN. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States. Diagn Microbiol Infect Dis 2000; 37:139-42.
8. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
9. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163:1730-54.
10. Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study. Antimicrob Agents Chemother 1999; 43:2612-23.
11. Sahm DF, Peterson DE, Critchley IA, Thornsberry C. Analysis of ciprofioxacin activity against Streptococcus pneumoniae after 10 years of use in the United States. Antimicrob Agents Chemother 2000; 44:2521-4.
12. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 5:800-4.
13. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. Active Bacterial Core Surveillance/Emerging Infections Program Network. JAMA 2001; 286:1857-62.
14. Chen DK, McGeer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-9.
15. Goldsmith CE, Moore JE, Murphy PG, Ambler JE. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J Antimicrob Chemother 1998; 41:420-1.
16. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341:1546-8.
17. Alou L, Ramirez M, García-Rey C, Prieto J, de Lencastre H. Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain: clonal diversity and appearance of ciprofloxacin-resistant epidemic clones. Antimicrob Agents Chemother 2001; 45:2955-7.
18. Ho P-L, Que T-L, Tsang DN-C, et al. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999; 43:1310-3.
19. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 26:1917-24.
20. Castillo EM, Rickman LS, Brodine SK, Ledbetter EK, Kelly C. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000; 28:239-43.
21. NCCLS Methods for dilution antimicrobial susceptibility, tests for bacteria that grow aerobically. 4th ed, vol 17, no. 2. Approved standard M7-A4. Wayne, PA: NCCLS, 1997.
22. NCCLS. Performance standards for antimicrobial susceptibility testing. 12th informational supplement. Approved standard, document M100-S12. Wayne, PA: NCCLS, 2002.
23. Zhanel GG, Waiters M, Laing N, Hobart DJ. In vitro pharmacodynamic modeling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47:435-40.
24. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001; 45:673-8.
25. Peterson DE, Sahm DF. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341:1547-8.
26. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325-37.
27. Hooper DC. Expanding uses of fluoroquinolones: opportunities and challenges. Ann Intern Med 1998; 129:908-10.
28. Davies TA, Evangelista A, Pfleger S, Bush K, Sahm DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae isolated in the United States in 1992-1996 and 1999-2000. Antimicrob Agents Chemother 2002; 46:119-24.
29. Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 2000; 44:462-6.